Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

GMP Synthesis of Bulk Drug Testing

Solicitation Number: HHS-NIH-NIDA-SBSS-14-014
Agency: Department of Health and Human Services
Office: National Institutes of Health
Location: National Institute on Drug Abuse
  • Print
Sources Sought
Added: Dec 04, 2013 4:53 pm
The National Institute on Drug Abuse (NIDA) seeks capability statements from Small Businesses (e.g., 8(a), veteran-owned, service-disabled veteran-owned, HUBZone, small disadvantaged, and woman-owned small businesses). Offerors must provide the Good Manufacturing Practices (GMP) synthesis of bulk drug substances to the medications development program of NIDA for toxicological and clinical trials. Offerors must demonstrate the ability to manufacture bulk drug substances under both GMP following relevant Food and Drug Administration (FDA) guidance and regulations (e.g. Code of Federal Regulations Title 21) and non-GMP. Offerors must indicate experience in producing GMP and non-GMP drug substances in batch sizes of at least one kilogram or larger, appropriately store GMP and non-GMP materials on site, and maintain a facility in good standing with the FDA. Offerors must have onsite access to state-of-the-art equipment for analytical testing (high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), isotope ratio (IR), circular dichroism (CD) and nuclear magnetic resonance (NMR)). Offerors must show experience in preparing reports acceptable in format and substance for adaptation into a Chemistry, Manufacturing and Control (CMC) section for each drug substance for submission to the FDA in support of Investigational New Drug (IND) and New Drug Application (NDA) applications. To handle substances or starting materials under the Controlled Substance Act of 1970, offerors must possess Drug Enforcement Administration (DEA) Research and Manufacturing Registrations for Schedules II to V controlled substances and demonstrate the capability to obtain DEA Research and Manufacturing Registrations for Schedule I controlled substances.

The established NAICS code is 541712. Information sent should be relevant and specific in the technical area under consideration, on each of the following qualifications: (1) Experience: An outline of previous project, specific GMP work and any in-house research and development efforts; (2) Personnel: Name, professional qualifications and specific experience of scientists, engineers and technical personnel who may be assigned as principal investigator and/or project director; (3) Facilities: Availability and description of special facilities required to perform synthesis, analysis, and storage of drug substances under GMP conditions, including security. Any other specific and relevant information about this particular area of procurement that would improve our consideration and evaluation of the information presented should be included. Interested organizations must demonstrate and document, in any capability statements submitted, extensive experience with and the ability to perform the above tasks. Organizations should demonstrate capability to administer and coordinate interrelated tasks in an effective and timely manner. Documentation may include, but not be limited to, contracts, both Government and commercial, that the organization has performed, references (i.e., names, titles, telephone numbers), and any other information serving to document the organization's capabilities (e.g., awards, commendation, etc.).

THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to a contractual agreement. This is not a request for proposals. The Government does not intend to award a contract based on responses under this announcement nor otherwise pay for preparing any information sent for the Government's use. Any proprietary information should be so marked. Small business concerns that believe they possess the capability necessary to successfully undertake the work described above should submit an original and two copies of their capability statement which minimally includes the following: 1) company name and address; 2) point of contact, 3) phone/fax/email; 4) NAICS Code(s) under which company business is conducted, 5) business type (i.e., women-owned, HUBZONE, etc.), size and status, and 6) capability information in response to the requirement and qualifications identified in this notice. Please submit written capability statements by December 18, 2013 to the NIDA Contracting Officer. Electronic copies of capability statements will also be accepted and can be emailed to Andrew Hotaling, Contract Specialist at
6001 Executive Boulevard
Room 4211 - MSC 9559
Bethesda, Maryland 20892
United States
Andrew Hotaling
Phone: 301.443.6677
Fax: 301.443.7595
Kenneth E Goodling,
Contracting Officer
Phone: (301)443-6677
Fax: (301)443-7595